CNP 015
Alternative Names: GT 015Latest Information Update: 09 Apr 2021
At a glance
- Originator Nonindustrial source; Queens University
- Developer Nonindustrial source; Vernalis
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial infarction; Neurological disorders
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 13 Feb 2006 No development reported - Preclinical for Myocardial infarction in Canada (unspecified route)
- 13 Feb 2006 No development reported - Preclinical for Neurological disorders in Canada (unspecified route)